866-997-4948(US-Canada Toll Free)

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 82 Pages


Global Markets Directs, \'Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Recurrent Glioblastoma Multiforme (GBM).
  • A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Recurrent Glioblastoma Multiforme (GBM) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) 8
Recurrent Glioblastoma Multiforme (GBM) Therapeutics under Development by Companies 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Products under Development by Companies 14
Companies Involved in Recurrent Glioblastoma Multiforme (GBM) Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Eli Lilly and Company 16
Antigenics, Inc. 17
Novartis AG 18
Eisai Co., Ltd. 19
Pfizer Inc. 20
ThromboGenics NV 21
Ascenta Therapeutics, Inc. 22
Tocagen Inc 23
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
lenvatinib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
axitinib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TB-403 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
onartuzumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dacomitinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
golvatinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AT-101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
buparlisib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
bevacizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bevacizumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
galunisertib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
golvatinib + lenvatinib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
G-200 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Drug Profile Updates 67
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products 80

Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Table


Number of Products Under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2013 8
Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
F. Hoffmann-La Roche Ltd., H1 2013 15
Eli Lilly and Company, H1 2013 16
Antigenics, Inc., H1 2013 17
Novartis AG, H1 2013 18
Pfizer Inc., H1 2013 20
ThromboGenics NV, H1 2013 21
Ascenta Therapeutics, Inc., H1 2013 22
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Drug Profile Updates 67
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products 80

List of Chart


Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2013 8
Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *